Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: author
Serval ID
serval:BIB_DE82EAE7E6C6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
Journal
Journal of Alzheimer's Disease
Author(s)
Lewczuk P., Popp J., Lelental N., Kölsch H., Maier W., Kornhuber J., Jessen F.
ISSN
1875-8908 (Electronic)
ISSN-L
1387-2877
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
28
Number
1
Pages
119-125
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Abstract
In this report, we confirm our previous findings of increased concentrations of soluble amyloid-β protein precursor (sAβPP) in cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) in a large cohort of patients (n = 314), not overlapping with those of our previous study, and we extend our observations by including a control group of participants with normal cognition. In addition, we investigate the effects of age, the APOEε4 genotype, and the blood-CSF barrier function on the concentrations of sAβPPα and sAβPPβ. The study participants were categorized according to clinical-neuropsychological criteria, supported by CSF neurochemical dementia diagnostics (NDD) analyses. sAβPPα concentrations in the AD group (132.0 ± 44.8) were significantly higher than in the control group (105.3 ± 37.3, p < 0.0005) but did not differ from the MCI-AD group (138.5 ± 39.5, p = 0.91). The MCI-AD group differed significantly from the MCI-O (97.3 ± 34.3, p < 0.05) group. There was no difference between the control and the MCI-O groups (p = 0.94). Similarly, sAβPPβ concentrations in the AD group (160.2 ± 54.3) were significantly higher than in the control group (129.9 ± 44.6, p < 0.005) but did not differ from the MCI-AD group (184.0 ± 56.4, p = 0.20). The MCI-AD group differed significantly from the MCI-O (127.8 ± 46.2, p < 0.05) group. There was no difference between the control and the MCI-O groups (p > 0.99). We observed highly significant correlation of the two sAβPP forms. Age and the CSF-serum albumin ratio were significant albeit weak predictors of the sAβPPα and sAβPPβ concentrations, while carrying the APOEε4 allele did not influenced the levels of the sAβPP forms. Taken together, the results strongly suggest that CSF sAβPP concentrations may be considered as an extension of already available NDD tools.
Keywords
Adult, Aged, Aged, 80 and over, Alzheimer Disease/cerebrospinal fluid, Alzheimer Disease/diagnosis, Amyloid beta-Protein Precursor/cerebrospinal fluid, Apolipoprotein E4/genetics, Biological Markers/cerebrospinal fluid, Cohort Studies, Female, Humans, Male, Middle Aged, Mild Cognitive Impairment/cerebrospinal fluid, Mild Cognitive Impairment/diagnosis
Pubmed
Web of science
Create date
25/10/2011 11:35
Last modification date
20/08/2019 17:03
Usage data